Licensing and Commercialization Agreement with Novartis Pharma AG (Tables)

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of the components of the Company's collaboration revenue

Below is a summary of the components of the Company’s collaboration revenue for the three months ended March 31, 2017 and March 31, 2016:

	Three months ended March 31,
	2017		2016
License revenue	$	—	$	—
Research and development activity revenue	1,658		1,275
API transfer revenue	—		14,443
Joint operating committee revenue	4		3
Total collaboration revenue	$	1,662	$	15,721